Compare Procter & Gamble Co (PG) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Tempus AI — how do they compare? Procter & Gamble Co trades at $150.16 (market cap $349.77B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Procter & Gamble Co is far larger — about 27.8× Tempus AI's market cap, and Procter & Gamble Co pays a 2.89% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Tempus AI for 22 Days on average.
| PG | TEM | |
|---|---|---|
Market Cap | $349.77B | $12.58B |
Volume | 10,055,825 | 7,444,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $167.18 | $99.28 |
52-Week Low | $138.10 | $41.55 |
Typical Hold Time | 131 Days | 22 Days |
Enterprise Value | $375.61B | $13.21B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $1.88. Strong fundamentals include $84.28B revenue, 18.44% net margin, and robust cash flow generation. Recent developments include a WNBA partnership and a dividend declaration of $1.09 payable in August 2026.
PG offers stable growth with premium valuation metrics (P/E 22.33, P/S 4.11) supported by strong brand equity and dividend consistency. Risks include premium valuation concerns amid modest growth outlook and competitive pressures. Analyst consensus is bullish with a $160.13 price target, though near-term upside may be limited given current price proximity to the lower target range.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
